In vitro susceptibility testing of ceftobiprole against 880 European respiratory tract infection isolates of methicillin-resistant Staphylococcus aureus followed by whole genome sequencing of ceftobiprole-resistant isolates

Diagn Microbiol Infect Dis. 2020 Apr;96(4):114978. doi: 10.1016/j.diagmicrobio.2019.114978. Epub 2019 Dec 27.

Abstract

Ceftobiprole was active (MIC, ≤2 mg/L) against most isolates (99.7%; 877/880) of methicillin-resistant Staphylococcus aureus from respiratory tract infections collected in 14 European countries during 2016-2017. Whole-genome sequence analysis showed that two of the three ceftobiprole-resistant (MIC, 4 mg/L) isolates identified were clonal complex 8 (CC8) and one was CC5, and that different mutations were present in genes encoding penicillin-binding proteins, mecA, and other proteins in each ceftobiprole-resistant isolate.

Keywords: Ceftobiprole; Europe; MRSA; Staphylococcus aureus; Whole genome sequencing.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacterial Proteins / genetics
  • Cephalosporins / pharmacology*
  • Drug Resistance, Bacterial
  • Europe
  • Genome, Bacterial
  • Humans
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Methicillin-Resistant Staphylococcus aureus / genetics*
  • Microbial Sensitivity Tests
  • Mutation
  • Penicillin-Binding Proteins / genetics
  • Respiratory Tract Infections / microbiology*
  • Staphylococcal Infections / microbiology
  • Whole Genome Sequencing

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Cephalosporins
  • Penicillin-Binding Proteins
  • mecA protein, Staphylococcus aureus
  • ceftobiprole